Wall Street brokerages forecast that Advaxis, Inc. (NASDAQ:ADXS) will report ($1.37) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Advaxis’ earnings. Advaxis posted earnings of ($4.35) per share in the same quarter last year, which would suggest a positive year over year growth rate of 68.5%. The company is scheduled to report its next quarterly earnings results on Thursday, January 9th.

On average, analysts expect that Advaxis will report full year earnings of ($2.70) per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of ($2.41) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Advaxis.

Advaxis (NASDAQ:ADXS) last announced its earnings results on Monday, September 9th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.24. Advaxis had a negative net margin of 113.67% and a negative return on equity of 67.08%. The business had revenue of $0.01 million for the quarter.

Separately, Zacks Investment Research lowered shares of Advaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th.

Shares of NASDAQ ADXS traded up $0.12 during trading on Monday, hitting $0.63. The company had a trading volume of 20,635,094 shares, compared to its average volume of 2,440,179. The stock has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $1.04. Advaxis has a fifty-two week low of $0.21 and a fifty-two week high of $10.80. The firm has a market capitalization of $10.85 million, a price-to-earnings ratio of -0.03 and a beta of 3.43.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sabby Management LLC grew its position in shares of Advaxis by 3,547.9% in the third quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock valued at $403,000 after purchasing an additional 1,480,260 shares during the period. Vanguard Group Inc. lifted its stake in shares of Advaxis by 71.1% in the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after buying an additional 95,607 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Advaxis by 143.7% in the second quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after buying an additional 295,444 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Advaxis by 53,633.7% in the second quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after buying an additional 50,952 shares in the last quarter. Institutional investors and hedge funds own 30.33% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.